We are aware that with the rapid development of melanoma drugs, patients with cutaneous melanoma, due to their high tumor mutational burden and a high proportion of BRAF mutations (at least 50%) (18, 19), have shown a more favorable prognosis compared to other subtypes. The gene discussed is BRAF; the disease is melanoma.